+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07828015

Evaluating Bevacizumab Versus Thalidomide After Nasal Electrocoagulation for Severe Hereditary Hemorrhagic Telangiectasia

Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-09-18

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of bevacizumab to treat severe hereditary hemorrhagic telangiectasia HHT, a rare genetic disorder that causes frequent nosebleeds and abnormal blood vessel formations in multiple organs. This Phase 2 study aims to assess the effectiveness and safety of bevacizumab compared to thalidomide, while also exploring how clinical and genetic factors affect treatment outcomes and understanding the reasons behind different patient responses. Participants will undergo nasal electrocoagulation surgery followed by treatment with either intravenous bevacizumab, given at 5 mgkg one to two times per year starting one month after surgery, or oral thalidomide at 50 mg twice daily beginning one month after surgery. The study compares these two approaches to identify optimal individualized therapies for severe HHT-related bleeding. Throughout the study, participants will be monitored at 1, 3, 6, and 12 months after surgery with assessments including the Epistaxis Severity Score ESS and hemoglobin levels to evaluate treatment effects. Safety and adverse events will be tracked, and the study will gather clinical and genetic data to investigate factors influencing treatment response. The total study duration extends up to 12 months of follow-up after surgery and treatment initiation.

CONDITIONS

Brief Title

Bevacizumab in the Treatment of HHT

Research Team

H

Hong-gang Duan, doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here